% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/BreastSubtypeR_methods.R
\name{BS_Multi}
\alias{BS_Multi}
\title{Intrinsic Subtyping with Multiple Approaches (BS_Multi)}
\usage{
BS_Multi(data_input, methods = "AUTO", Subtype = FALSE, hasClinical = FALSE)
}
\arguments{
\item{data_input}{The output from the \code{\link[=Mapping]{Mapping()}} function, containing
processed gene expression data prepared for subtyping.}

\item{methods}{Character vector specifying the subtyping methods to run.
Available options include:
\itemize{
\item \code{"parker.original"}: Original PAM50 (Parker et al., 2009).
\item \code{"genefu.scale"}: PAM50 (scaled version; Gendoo et al., 2016).
\item \code{"genefu.robust"}: PAM50 (robust version; Gendoo et al., 2016).
\item \code{"cIHC"}: Conventional ER-balancing with immunohistochemistry (Ciriello et al., 2015).
\item \code{"cIHC.itr"}: Iterative ER-balancing (Curtis et al., 2012).
\item \code{"PCAPAM50"}: PCA-based PAM50 using ESR1 balancing (Raj-Kumar et al., 2019).
\item \code{"ssBC"}: Subgroup-specific gene-centering (Zhao et al., 2015).
\item \code{"ssBC.v2"}: Updated subgroup-specific centering (Fernandez-Martinez et al., 2020).
\item \code{"AIMS"}: Absolute Intrinsic Molecular Subtyping (Paquet & Hallett, 2015).
\item \code{"sspbc"}: SSPBC, a large-cohort SSP trained on SCAN-B (Staaf et al., 2022).
\item \code{"AUTO"}: Cohort-aware selection of compatible methods (must be the only entry).
}

\strong{Notes:}
\itemize{
\item If \code{"AUTO"} is selected, it must be the sole value in \code{methods}.
\item Otherwise, at least \strong{two} methods must be specified.
}}

\item{Subtype}{Logical. If \code{TRUE}, returns four subtypes (Luminal A, Luminal B,
HER2-enriched, Basal-like), excluding Normal-like.}

\item{hasClinical}{Logical. If \code{TRUE}, incorporates clinical data from
\code{colData(se_obj)}. Required columns:
\itemize{
\item \code{"TSIZE"}: Tumor size (\code{0} = ≤2 cm; \code{1} = >2 cm).
\item \code{"NODE"}: Lymph node status (\code{0} = negative; \verb{≥1} = positive; must be numeric).
}}
}
\value{
A list containing per-method subtype assignments for each sample.
}
\description{
Executes multiple intrinsic molecular subtyping methods in parallel.
Users can either specify a set of classifiers directly, or enable the
\strong{AUTO mode}, which dynamically selects methods based on cohort composition
(e.g., ER/HER2 distribution, subtype purity, subgroup size).
AUTO reduces misclassification in skewed or subtype-specific cohorts by
disabling methods whose assumptions are violated, but does not perform
consensus voting—subtypes are still returned per method.
}
\examples{
## Example: run multiple methods
data("OSLO2EMIT0obj")
methods <- c("parker.original", "genefu.scale", "genefu.robust")
res.test <- BS_Multi(
  data_input = OSLO2EMIT0obj$data_input,
  methods = methods,
  Subtype = FALSE,
  hasClinical = FALSE
)

}
\references{
Yang Q, Hartman J, Sifakis EG.
\emph{BreastSubtypeR: A Unified R/Bioconductor Package for Intrinsic Molecular Subtyping in Breast Cancer Research.}
NAR Genomics and Bioinformatics. 2025. https://doi.org/10.1093/nargab/lqaf131. Selected as Editor’s Choice.

Parker JS, Mullins M, Cheung MCU, Leung S, Voduc D, et al.
\emph{Supervised risk predictor of breast cancer based on intrinsic subtypes.}
J Clin Oncol. 2009;27(8):1160-1167. https://doi.org/10.1200/JCO.2008.18.1370

Gendoo DMA, Ratanasirigulchai N, Schröder MS, Paré L, Parker JS, Prat A, et al.
\emph{Genefu: An R/Bioconductor package for computation of gene expression-based signatures in breast cancer.}
Bioinformatics. 2016;32(7):1097-1099. https://doi.org/10.1093/bioinformatics/btv693

Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al.
\emph{Comprehensive molecular portraits of invasive lobular breast cancer.}
Cell. 2015;163(2):506-519. https://doi.org/10.1016/j.cell.2015.09.033

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al.
\emph{The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.}
Nature. 2012;486(7403):346-352. https://doi.org/10.1038/nature10983

Zhao X, Rodland EA, Tibshirani R, Plevritis S.
\emph{Molecular subtyping for clinically defined breast cancer subgroups.}
Breast Cancer Res. 2015;17(1):29. https://doi.org/10.1186/s13058-015-0520-4

Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, et al.
\emph{Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant Phase III trial of paclitaxel–trastuzumab with or without lapatinib in HER2-positive breast cancer.}
J Clin Oncol. 2020;38(36):4184-4197. https://doi.org/10.1200/JCO.20.01276

Paquet ER, Hallett MT.
\emph{Absolute assignment of breast cancer intrinsic molecular subtype.}
J Natl Cancer Inst. 2015;107(1):dju357. https://doi.org/10.1093/jnci/dju357

Staaf J, Häkkinen J, Hegardt C, Saal LH, Kimbung S, Hedenfalk I, et al.
\emph{RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer.}
NPJ Breast Cancer. 2022;8(1):27. https://doi.org/10.1038/s41523-022-00465-3
}
